Clinical trial
Safety, Tolerability and Pharmacodynamics of Single Rising Intravitreal and Multiple Rising Intravitreal Doses of BI 836880 in Patients With wAMD (Open Label, Non-randomized, Uncontrolled).
NCT03861234 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Tolerability and Pharmacodynamics of Single Rising Intravitreal and Multiple Rising Intravitreal Doses of BI 836880 in Patients With wAMD (Open Label, Non-randomized, Uncontrolled).
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 27, 2019
- Completion date
- November 1, 2023
- Enrollment
- 43 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.